PMID: 12201620Aug 31, 2002Paper

Switching antipsychotic medications: general recommendations and switching to amisulpride

Current Medical Research and Opinion
T BurnsK Demyttenaere


As more and more novel antipsychotic agents are introduced, the need for practical guidelines on switching these medications is becoming increasingly important. Indications for a switch include situations where the patient or his family/caregiver requests a change in medication, where the patient cannot tolerate current treatment, where they have comorbid physical or psychiatric conditions or where they have achieved only a partial remission, are refractory to treatment or have relapsed. Cross-tapering is generally the most acceptable method of switching, although abrupt withdrawal may be necessary in some cases, such as when a patient develops a severe or acute reaction to their current treatment. Possible problems of switching include the risk of discontinuation reactions and the re-emergence of psychotic symptoms. The pharmacological profile of amisulpride means it has a relatively low potential for interactions with other drugs and may be started while discontinuing the previous antipsychotic. It should be started at the target dose for the patient's current symptoms. A retrospective questionnaire among 60 patients switching to amisulpride treatment was undertaken to identify the characteristics of patients switching antips...Continue Reading


Feb 1, 1990·Acta Psychiatrica Scandinavica·B SpivakH Munitz
Apr 1, 1989·Archives of General Psychiatry·A C NelliI Feinberg
Mar 1, 1981·Psychosomatics·J Lieberman
Jan 1, 1995·Schizophrenia Bulletin·D ShoreJ A Lieberman
Jun 1, 1995·Journal of Clinical Psychopharmacology·J M RadfordR L Borison
Mar 1, 1995·Archives of General Psychiatry·R J Wyatt
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·P BoyerF Aubin
Mar 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·A E Lang
Nov 1, 1995·International Clinical Psychopharmacology·J CarmanA Vangeneugden
Jan 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·H LooO Fleurot
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·D Taylor
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·J C SpellerJ L Alberts
Sep 1, 1999·International Clinical Psychopharmacology·C Coulouvrat, L Dondey-Nouvel
Apr 1, 1997·Journal of Clinical Psychopharmacology·S A ChongH S Lee
Oct 14, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·P CarrièreT Lempérière
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling

❮ Previous
Next ❯


Jun 27, 2009·Neuropsychiatric Disease and Treatment·Ann M Mortimer
Jul 5, 2008·Clinical Drug Investigation·Luca PaniKöksal Alptekin
Jul 20, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Prakash S Masand
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Patrice Boyer
Aug 28, 2013·International Journal of Psychiatry in Medicine·Miguel Gutiérrez FraileJulio Bobes García
Dec 1, 2004·Acta Neuropsychiatrica·Pierre ChueLili Kopala
Oct 1, 2019·Expert Opinion on Drug Safety·Wade MarteeneDan Siskind
Apr 2, 2016·Journal of Clinical Psychopharmacology·Ambreen K GhoriRajesh R Tampi
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here